Dr. Reddy’s Launches First Generic Semaglutide Injection in Canada After Health Canada Nod
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Dr Reddy’s Laboratories ( (RDY) ) has shared an announcement.
On May 15, 2026, Dr. Reddy’s Laboratories announced the launch of its generic Semaglutide Injection in Canada for once-weekly treatment of adults with type 2 diabetes, following a Notice of Compliance from Health Canada issued on April 28, 2026. The product is supplied as a sterile solution in pre-filled pens in 2 mg/pen and 4 mg/pen strengths, offering multiple dosing options in combination with diet and exercise and various background therapies.
Dr. Reddy’s is the first company to receive Health Canada approval for a generic Semaglutide Injection, making Canada the first G7 country to authorize a generic version of this GLP-1 therapy. The move underscores the company’s expertise in complex peptide drugs, builds on its recent Semaglutide launch in India under the Obeda brand, and strengthens its positioning in the growing GLP-1 segment while improving access to advanced diabetes treatments for Canadian patients.
The most recent analyst rating on (RDY) stock is a Buy with a $16.90 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Neutral.
The score is driven mainly by solid but weakening fundamentals (margin/ROE compression and higher debt despite growth) and a balanced earnings-call outlook that points to FY27 margin recovery but highlights near-term profitability and working-capital risks. Technicals are neutral-to-soft and valuation support is limited given the P/E and low yield.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories is a global pharmaceutical company headquartered in Hyderabad, India, founded in 1984 and focused on providing affordable and innovative medicines. The company’s portfolio spans APIs, generics, branded generics, biosimilars and OTC products, with key therapeutic areas including gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology, and major markets across the U.S., India, Russia & CIS, China, Brazil and Europe.
Average Trading Volume: 2,548,032
Technical Sentiment Signal: Hold
Current Market Cap: $11.33B
For a thorough assessment of RDY stock, go to TipRanks’ Stock Analysis page.
